Journal article
Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
Frontiers in pediatrics, Vol.10, pp.1005098-1005098
10/13/2022
DOI: 10.3389/fped.2022.1005098
PMCID: PMC9606656
PMID: 36313874
Abstract
Venous thromboembolism is a major hospital acquired complication in the pediatric population over the last two-decades, with a 130% increase in the past decade. Direct oral anticoagulants (DOACs) are a newer class of anticoagulant medication for the treatment and prophylaxis of VTEs that provide the primary advantages of an oral route of administration without a requirement to adjust dosing to achieve a therapeutic level. It is anticipated that these medications will quickly replace parenteral anticoagulants and clinicians should familiarize themselves with DOACs. In this article, we provide an overview of the pharmacological properties of DOACs, with a specific focus on rivaroxaban and dabigatran, which have been approved for use in pediatric patients. Each drug's characteristics are discussed along with data from their respective clinical trials.
Details
- Title: Subtitle
- Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
- Creators
- Maha Al-Ghafry - Royal HospitalAnjali Sharathkumar - , , , ,
- Resource Type
- Journal article
- Publication Details
- Frontiers in pediatrics, Vol.10, pp.1005098-1005098
- DOI
- 10.3389/fped.2022.1005098
- PMID
- 36313874
- PMCID
- PMC9606656
- NLM abbreviation
- Front Pediatr
- ISSN
- 2296-2360
- eISSN
- 2296-2360
- Publisher
- Frontiers Media S.A
- Language
- English
- Date published
- 10/13/2022
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984353864602771
Metrics
9 Record Views